Condition : New
0
From UAE
To United States
in 5-10 days
Description
How It Works
Nivolumab is a PD-1 (programmed death-1) inhibitor, while relatlimab is a LAG-3 (lymphocyte-activation gene 3) inhibitor. Both drugs work by blocking the pathways that cancer cells use to evade the immune system. Nivolumab inhibits the PD-1 pathway, which allows T cells to recognize and attack cancer cells. Relatlimab inhibits the LAG-3 pathway, which further enhances the T cell response against tumors. Together, these drugs provide a synergistic effect, boosting the immune system’s ability to target and destroy cancer cells.Side Effects
- Fatigue
- Diarrhea
- Rash
- Pruritus (itching)
- Nausea
- Decreased appetite
- Musculoskeletal pain
- Infusion-related reactions
- Elevated liver enzymes
- Hypothyroidism
- Pneumonitis
- Colitis
Indications
- Advanced or metastatic melanoma
- Other cancers as determined by ongoing clinical trials and approvals
Contraindications
- Severe hypersensitivity to nivolumab, relatlimab, or any of the excipients in the formulation
- Pregnancy and breastfeeding (due to potential harm to the fetus or infant)
Price Comparison in Different Countries
Country | Price (per injection) | Reference |
---|---|---|
Pakistan | Approximately PKR 800,000 | medicalstore.com.pk Pakistan |
United States | USD 10,000 | GoodRx |
United Kingdom | GBP 7,500 | NHS UK |
Canada | CAD 12,000 | Health Canada |
Australia | AUD 15,000 | PBS Australia |
Top 5 Global Pharmaceutical Brands
- Pfizer
- Novartis
- Roche
- Sanofi
- GlaxoSmithKline (GSK)